Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment.

abstract：:The effect of association of hyperthermia with the anti-inflammatory drug rhein (RH), 4,5-dihydroxyanthraquinone-2-carboxylic acid, on the clonogenic activity of human glioma cells has been examined. RH inhibits neoplastic growth mainly through an ATP depletion, but thermal cell killing is not mediated by the drug-ind...

journal_title：Anti-cancer drugs

authors： Floridi A,Gentile PF,Bruno T,Delpino A,Iacobini C,Benassi M

更新日期：1992-08-01 00:00:00

abstract：:Epirubicin is usually administered in combination with other cytotoxics. Few pharmacological studies address whether relevant clinical interactions occur in vitro between these drugs. This study investigated whether epirubicin interacted with other cytotoxics or anti-emetics. The following drugs were prepared at pharm...

journal_title：Anti-cancer drugs

authors： Zhang W,Zalcberg JR,Cosolo W

更新日期：1992-12-01 00:00:00

abstract：:Cryptophycin (CP)-52, a synthetic analog of CP-1, possesses potent and selective antiproliferative activity against human solid tumors both and. Based on an algorithm developed in this laboratory using HCT-116 human colon adenocarcinoma cells, CP-52 exhibited a time- and concentration-dependent antiproliferative effec...

journal_title：Anti-cancer drugs

authors： Subramanian B,Nakeff A,Media JE,Wiegand RA,Valeriote FA

更新日期：2002-11-01 00:00:00

abstract：:In our institution, 103 glioblastoma multiforme (GBM) patients aged from 55 to 83 years were treated since November 1994 as follows. All patients underwent surgical intervention (gross total resection, n = 35; subtotal resection, n = 38; stereotactic biopsy, n = 30). Subsequently all patients were offered radiotherapy...

journal_title：Anti-cancer drugs

authors： Piribauer M,Fazeny-Dörner B,Rössler K,Ungersböck K,Czech T,Killer M,Dieckmann K,Birner P,Prayer D,Hainfellner J,Muhm M,Marosi C

更新日期：2003-02-01 00:00:00

abstract：:Since the number of patients seen in a pediatric oncology center is relatively small, it is difficult to perform single drug phase two studies, even on a national base. This also probably explains the lack of information on ifosfamide, despite the fact that it has now been used for more than 10 years in pediatrics. As...

journal_title：Anti-cancer drugs

authors： de Kraker J

更新日期：1991-08-01 00:00:00

abstract：:Analog II (1,1-dichloro-cis-2,3-diarylcyclopropane), previously shown to be a pure antiestrogen in mice, was examined for potential antitumor activity on human breast cancer cells in culture. In this study, Analog II produced a dose-related antiproliferative effect on the growth of estrogen receptor (ER)-positive MCF-...

journal_title：Anti-cancer drugs

authors： Jain PT,Rajah TT,Pento JT

更新日期：1997-11-01 00:00:00

abstract：:Human colon cancer SW480 cells express the c-myc gene. On the other hand, SW480DDP cell lines resistant to cisplatin exhibited decreased c-myc gene expression, but their cell growth rates remained similar to those of their parental cells. Antisense oligonucleotides to c-myc inhibited c-myc expression and induced incre...

journal_title：Anti-cancer drugs

authors： Funato T,Kozawa K,Kaku M,Sasaki T

更新日期：2001-11-01 00:00:00

abstract：:Between March and September 1988, 74 patients with progressive ovarian cancer after prior platinum-based therapy were treated with the luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin (Decapeptyl degrees). Treatment consisted of i.m. injection of 3.75 mg of microencapsulated Triptorelin on days 1, 8 an...

journal_title：Anti-cancer drugs

authors： Duffaud F,van der Burg ME,Namer M,Vergote I,Willemse PHB,ten Bokkel Huinink W,Guastalla JP,Nooij,Kerbrat P,Piccart M,Tumolo S,Favalli G,van der Vange N,Lacave AJ,Wils J,Splinter TA,Einhorn N,Roozendaal KJ,Rosso R,Ve

更新日期：2001-02-01 00:00:00

abstract：:The goal of our study was to determine whether an apoptosis assay used after short-term drug exposure could predict selective toxicity to cancer cells. To this end we compared the effect of eight anticancer drugs and 10 toxic compounds without known antitumor activity in cultures of human breast cancer cells and norma...

journal_title：Anti-cancer drugs

authors： Frankfurt OS,Krishan A

更新日期：2003-08-01 00:00:00

abstract：:13,14-Dihydro-15-deoxy-Delta7-prostaglandin A1 methyl ester (TEI-9826), an antitumor prostaglandin analog, is a candidate for clinical trial. In the present study, we examined its biological stability in vitro, antitumor activity in vitro and in vivo, and pharmacokinetics. Although TEI-9826 was rapidly hydrolyzed to t...

journal_title：Anti-cancer drugs

authors： Fukushima S,Takeuchi Y,Kishimoto S,Yamashita S,Uetsuki K,Shirakawa S,Suzuki M,Furuta K,Noyori R,Sasaki H,Kikuchi Y,Kita T,Yamori T,Sawada J,Kojima M,Hazato A,Kurozumi S,Fukushima M

更新日期：2001-03-01 00:00:00

abstract：:The role of pazopanib in the second-line setting of refractory metastatic transitional cell carcinoma of the urothelium has not been defined clearly. The aim of this phase I/II trial was to assess the safety, tolerability, and efficacy of combining pazopanib and vinflunine in patients with metastatic transitional cell...

journal_title：Anti-cancer drugs

authors： Gerullis H,Eimer C,Ecke TH,Georgas E,Arndt C,Otto T

更新日期：2013-04-01 00:00:00

abstract：:Targeting oncogenic signaling pathways by small molecules has emerged as a potential treatment strategy for cancer. reactivation of p53 and induction of tumor cell apoptosis (RITA) is a promising anticancer small molecule that reactivates p53 and induces exclusive apoptosis in tumor cells. Less well appreciated was th...

journal_title：Anti-cancer drugs

authors： Mobaraki RN,Karimi M,Alikarami F,Farhadi E,Amini A,Bashash D,Paridar M,Kokhaei P,Rezvani MR,Kazemi A,Safa M

更新日期：2018-10-01 00:00:00

abstract：:We present the case of a 70-year-old patient affected by metastatic castration-resistant prostate cancer. He underwent radical prostatectomy in 2007 and subsequent adjuvant radiotherapy and hormonal therapy for 2 years. In 2011, he developed bilateral lung metastases, and therefore he received chemotherapy (eight cycl...

journal_title：Anti-cancer drugs

authors： Bolzacchini E,Patriarca C,Giordano M

更新日期：2021-01-01 00:00:00

abstract：:The antitumor effect of etoposide (ETO) may be related to duration of exposure to a relatively low serum level while myelosuppression may be dependent on peak ETO serum levels. With regard to such therapeutic ranges, duration of exposure to predefined plasma ETO concentration ranges and the related AUC (expressed as p...

journal_title：Anti-cancer drugs

authors： Würthwein G,Krümpelmann S,Tillmann B,Real E,Schulze-Westhoff P,Jürgens H,Boos J

更新日期：1999-10-01 00:00:00

abstract：:Cantharidin is a natural toxin that possesses potent anti-tumor properties. Its clinical application, however, is limited due to severe side-effects. Its cytotoxicity is believed to be mediated by the inhibition of serine/threonine protein phosphatase 2A. In order to identify new compounds with potential clinical ther...

journal_title：Anti-cancer drugs

authors： Shan HB,Cai YC,Liu Y,Zeng WN,Chen HX,Fan BT,Liu XH,Xu ZL,Wang B,Xian LJ

更新日期：2006-09-01 00:00:00

abstract：:We performed a phase II, Southwest Oncology Group (SWOG) clinical trial of recombinant human interleukin-4 (rhuIL-4) in patients with previously treated non-Hodgkin's lymphoma (NHL). We studied 18 eligible patients with low-grade and 21 patients with intermediate- or high-grade NHL. All patients had received prior che...

journal_title：Anti-cancer drugs

authors： Taylor CW,LeBlanc M,Fisher RI,Moore DF Sr,Roach RW,Elias L,Miller TP

更新日期：2000-10-01 00:00:00

abstract：:α-Lipoic acid (α-LA) is a biogenic antioxidant that has been used successfully in the treatment of diabetic polyneuropathy and its application to many oxidative stress-associated chronic diseases has increased. In this study, we investigated the effect of α-LA on colorectal cancer cell growth and its underlying mechan...

journal_title：Anti-cancer drugs

authors： Yoo TH,Lee JH,Chun HS,Chi SG

更新日期：2013-07-01 00:00:00

abstract：:Linking chemotherapeutic drugs to a macromolecular carrier system may enhance tumor targeting, reduce toxicity and overcome drug resistance mechanisms. As an elementary model to evaluate the pharmacological properties of macromolecular drug carrier systems we chose rat serum albumin (RSA) for carrier and methotrexate ...

journal_title：Anti-cancer drugs

authors： Stehle G,Wunder A,Sinn H,Schrenk HH,Schütt S,Frei E,Hartung G,Maier-Borst W,Heene DL

更新日期：1997-10-01 00:00:00

abstract：:Bevacizumab has been shown to be effective combined with chemotherapy for first-line treatment of advanced colorectal cancer, but little information is available about its efficacy and safety in patients who may be candidates for surgery at any time during the disease. The case history of a female patient with colorec...

journal_title：Anti-cancer drugs

authors： Castro-Carpeño Jd,Moyano MS,Sáenz EC,Belda-Iniesta C,Batlle JF,Barón MG

更新日期：2009-04-01 00:00:00

abstract：:The combination of platinum and paclitaxel is the standard treatment of advanced ovarian carcinoma; however, recent studies have questioned the actual role of the combination as compared to either of the two agents alone. We report an open-label, two-center, phase II study of upfront paclitaxel for patients with histo...

journal_title：Anti-cancer drugs

authors： Gallardo-Rincón D,Pérez-Landeros L,Oñate-Ocaña LF,Mohar A,Calderillo G,de la Garza J,Cabrera P,Sánchez B,Dueñas-Gonzalez A

更新日期：2003-06-01 00:00:00

abstract：:RNA interference, a posttranscriptional gene-silencing mechanism, has received considerable attention for its potential as a new therapeutic strategy to treat human diseases and conditions including cancer. Various studies have supported a role for the R2 subunit of ribonucleotide reductase in cancer progression and m...

journal_title：Anti-cancer drugs

authors： Avolio TM,Lee Y,Feng N,Xiong K,Jin H,Wang M,Vassilakos A,Wright J,Young A

更新日期：2007-04-01 00:00:00

abstract：:A phase I/II study to determine the recommended dose for combination therapy with CPT-11 (irinotecan hydrochloride) and S-1 (tegafur, gimestat and otastat potassium) for advanced or recurrent gastric cancer, and to assess the safety and efficacy of this therapy. In the phase I portion of the study, S-1 was administere...

journal_title：Anti-cancer drugs

authors： Katsube T,Ogawa K,Ichikawa W,Fujii M,Tokunaga A,Takagi Y,Kochi M,Hayashi K,Kubota T,Aiba K,Arai K,Terashima M,Kitajima M

更新日期：2007-06-01 00:00:00

abstract：:Venetoclax is a first-in-class orally available, B-cell lymphoma (BCL)-2 inhibitor indicated for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) harboring the 17p deletion. We used a novel approach for evaluating venetoclax pharmacokinetics using only sparse sampling in 155 patien...

journal_title：Anti-cancer drugs

authors： Salem AH,Dunbar M,Agarwal SK

更新日期：2017-09-01 00:00:00

abstract：:Targeted cancer chemotherapy is a novel approach developed for the specific delivery of anticancer drugs. Tumour targeting can be achieved by combining a chemotherapeutic agent with a targeting moiety that recognizes tumour-specific or highly expressed receptors on cancer cells. We used the gonadotropin-releasing horm...

journal_title：Anti-cancer drugs

authors： Manea M,Tóvári J,Tejeda M,Schulcz A,Kapuvári B,Vincze B,Mezo G

更新日期：2012-01-01 00:00:00

abstract：:It is crucial to incorporate new and more potent antineoplastic agents in treating non-Hodgkin's lymphoma since standard chemotherapy fails to cause a significant increase in the survival rate. A potential chemotherapeutic agent is dolastatin 10; hence, the objective of our study is to investigate the effect of the an...

journal_title：Anti-cancer drugs

authors： Maki A,Mohammad R,Raza S,Saleh M,Govindaraju KD,Pettit GR,al-Katib A

更新日期：1996-05-01 00:00:00

abstract：:Rats received an intraperitoneal bolus injection of etoposide at 5 mg/kg of body weight in the form of an etoposide microcrystal suspension in oil (ETOP-OIL) or an aqueous etoposide solution. The tissue distribution was subsequently analyzed using high performance liquid chromatography. ETOP-OIL delivered significantl...

journal_title：Anti-cancer drugs

authors： Hagiwara A,Takahashi T,Lee M,Sakakura C,Shoubayashi S,Tashima S,Yamamoto A,Muranishi S

更新日期：1993-02-01 00:00:00

abstract：:Our objective was to determine the maximum tolerated dose (MTD) of paclitaxel when given as a 7 day continuous i.v. infusion, repeated every 3 weeks, and to evaluate the toxicity and the efficacy of such a schedule of administration as a salvage treatment in ovarian cancer patients pretreated and refractory to 3 or 24...

journal_title：Anti-cancer drugs

authors： Soulié P,Trandafir L,Taamma A,Lokiec F,Brain E,Delord JP,Mita A,Vannetzel JM,Cvitkovic E,Misset JL

更新日期：1997-09-01 00:00:00

abstract：:Continuous exposure to daunorubicin (DNR) confers resistance against the drug-elicited lethality of leukemic cells and then reduces the remission rate. However, the detailed mechanisms involved in resistance development of leukemic cells to DNR remain unclear. Upregulation of aldo-keto reductases (AKRs) in human leuke...

journal_title：Anti-cancer drugs

authors： Matsunaga T,Yamaguchi A,Morikawa Y,Kezuka C,Takazawa H,Endo S,El-Kabbani O,Tajima K,Ikari A,Hara A

更新日期：2014-09-01 00:00:00

abstract：:Studies have shown that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in cancer cells. However, breast cancer cells are generally resistant to TRAIL. In the present study, we explored the effect of bufalin on TRAIL-induced breast cancer cell apoptosis. The results showed...

journal_title：Anti-cancer drugs

authors： Yan S,Qu X,Xu L,Che X,Ma Y,Zhang L,Teng Y,Zou H,Liu Y

更新日期：2014-07-01 00:00:00

abstract：:Phase II trials of the novel biologic combination of 13-cis-retinoic acid plus interferon (IFN)-alpha have achieved major activity in advanced squamous cell carcinomas of the skin and cervix, but not of the lung or head and neck. Very limited study of this combination has occurred in cancers other than those of squamo...

journal_title：Anti-cancer drugs

authors： Kudelka AP,Freedman RS,Edwards CL,Lippman SM,Tornos CS,Krakoff IH,Kavanagh JJ

更新日期：1993-06-01 00:00:00